Aalberts: highlights ING Benelux Conference Brussels 2024, Ackermans & Van Haaren: Highlights ING Benelux Conference Brussels,Ackermans & Van Haaren: Strong operational performance of underlying companies and guidance fine-tuned upwards, AMG: Highlights ING Benelux Conference Brussels, Aperam: Highlights ING Benelux Conference Brussels, Arcadis: Highlights ING Benelux conference, Azelis: Highlights ING Benelux Conference Brussels, Bekaert: Guidance cut and €200m buyback as sweetener, CFE: No new...
SBM Offshore completes US$1.5 billion financing of Jaguar Amsterdam, November 21, 2024 SBM Offshore announces it has completed the project financing of FPSO Jaguar for a total of US$1.5 billion. The project financing was fully secured by a consortium of 16 international financial institutions. The Company expects to draw the loan phased over the construction period of the FPSO. The project loan is in line with the duration of the construction phase. The FPSO Jaguar’s design is based on SBM Offshore’s industry leading Fast4Ward® program that incorporates the Company’s seventh new build, ...
Weekly share repurchase program transaction details November 20, 2024 SBM Offshore reports the transaction details related to its EUR130 million (c. US$140 million) share repurchase program for the period November 14, 2024 through November 20, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024, effective from March 1, 2024 and increased by EUR65 million as announced on August 8, 2024. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. In...
UCB has received a 5th nod for Bimzelx as hidradenitis suppurativa joins the fray of approved indications. We see an important role for Bimzelx in this emerging disease space with clear potential to become standard of care over time given its clear outperformance over Novartis' Cosentyx in the clinic. We reiterate our € 173 TP and Accumulate rating.
>Sub-par EBIT almost offset by interest expenses and taxation in H1 2024/25 - Like-for-like sales increased 6.1% in H1 2024/25 (Fresh: 6.5%, Long Fresh: 4.5%), which was ahead of our estimate (3.5% group). Adjusted EBITDA was € 94.4m, in line with our estimate. EBIT was € 31m, which is materially below our forecast. Greenyard mentions reorganisation costs (€ 4.5m), and higher depreciation. Although a notch below our estimate, finance costs are high at € 26m in H1 2024...
UCB shared first insights into the Phase 3 data on dapimap in SLE, which appear generally favourable with a 14.6% BICLA benefit after 48 weeks vs. SoC. The data also shows a steroid tapering effect and reduction in flares, while suggesting possible outperformance vs. current market leader Benlysta (GSK). Dapimap is co-developed with Biogen and will be continued in a second Ph3 study. We reiterate our € 173 TP and Accumulate rating.
After successfully navigating its business during two challenging years in 2022 and 2023, which were marked by unseen inflation, Greenyard reached in 1H24/25 operational results in line with our model with increased net sales and a further improvement of its Adj. EBITDA driven by sustained volume growth particularly in the Fresh segment and by managing optimal price levels across as well its Fresh as in its Long Fresh division. We welcome the reduction of both debt and leverage ratio (from 2.39x...
Greenyard will publish its 1H24/25 results (1 April to 30 September) on Tuesday, 19 November, at 7am CET. During the last AGM in September, Greenyard did not provide any guidance for the current year or half year. We expect 1H24/25F sales to be up by 4.8% YoY to €2.64bn, driven by 1.7% inflation and FX effects, with 3.3% volume growth in Greenyard's Fresh segment and 2.3% volume growth in the Long Fresh segment. Greenyard is currently trading at a discount to our peer group median EV/EBITDA valu...
EVS indicated that after 3Q24 they are on track to achieve FY24 revenue and profit at the higher end range of its guidance (revenue guidance of € 190 to €200m (KBCSe € 197.1m) and EBIT guidance €40 to 46m (KBCSe € 44.1m)). Next to the positive impact of its revenue performance on its gross profit, EVS sees an increasing gross margin performance on all its solutions. For this EVS refers to a well balanced pricing strategy. Without giving exact numbers, they highlight that this results in an overa...
EVS Q3 2024 business update EVS Q3 2024 business update Reaffirming growth expectations for 2024, setting a new revenue high for EVS, while actively building the future Liège, Belgium | November 14th, 2024 EVS’ financial results are firming up in line with expectations. While the final weeks of production and deliveries are being planned, we primarily focus on building the future. Order intake for the fourth quarter looks promising, ensuring a kick start in 2025. We have significant commercial opportunities in the pipeline, which are bound to play a substantial role in our future suc...
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
>Another strong set of results as SBM looks forward to FPSO sales - PSO Sale. The company indicated that its FPSO Prosperity was sold to ExxonMobil Guyana Ltd on November 7 whereas it expects the sales of FPSO Liza Destiny to be on track, expecting it to close by the end of the year. Contract award: The company announced that it has been awarded an FPSO contract as part of the GranMorgu field development project in Suriname. According to the company, the c. 220 k...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.